Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 40 min ago
Peer-reviewedCC BY 4.0Hla

Association of HLA‐B Leader With BK Polyomavirus and Cytomegalovirus Infections in Kidney Allograft Recipients

4 affiliations
  1. 1Clinic for Transplantation Immunology and Nephrology University Hospital Basel Basel Switzerland
  2. 2Translational Virus Immunity Pathology, Immunology Research, Department of Medical Biology UiT The Arctic University of Norway Tromsø Norway
  3. 3Translational Virus Immunity Pathology, Institute of Experimental Immunology University of Zurich Zurich Switzerland
  4. 4HLA‐Diagnostics and Immunogenetics, Department of Laboratory Medicine University Hospital Basel Basel Switzerland

Abstract

Natural killer (NK) cell education and function depend on HLA‐E expression, influenced by the dimorphic HLA‐B leader peptide (−21M vs. −21T). NK cells help control BK polyomavirus (BKPyV) and cytomegalovirus (CMV) after kidney transplantation, but the HLA‐B leader's role is unclear. We retrospectively studied 700 kidney transplants with high‐resolution recipient/donor HLA typing, determining the recipient's HLA‐B leader genotype (MM 6%, MT 39%, TT 55%) and recipient/donor constellation (345/700 [49%] matched, 355/700 [51%] mismatched). Associations with 1‐year occurrence and severity of BKPyV (decoy cell shedding, BKPyV‐DNAemia, presumptive BKPyV‐associated nephropathy [BKPyVAN]) and CMV (DNAemia, disease) were assessed with univariate analyses and multivariable Cox and logistic regression. One‐year incidence of decoy cell shedding was similar across genotypes (MM 28.3%, MT 29.0%, TT 33.5%; p = 0.37) and between matched and mismatched recipients (31.0% vs. 31.8%; p = 0.79); BKPyV‐DNAemia incidence likewise did not differ by genotype (MM 19.6%, MT 16.5%, TT 18.9%; p = 0.73) or constellation (15.9% vs. 20.0%; p = 0.16). In multivariable models, neither genotype nor constellation was associated with decoy cell shedding, BKPyV‐DNAemia, or development of presumptive BKPyVAN. CMV‐DNAemia incidence also did not differ by genotype (MM 19.6%, MT 30.9%, TT 28.8%; p = 0.35) or constellation (27.0% vs. 31.0%; p = 0.25). In multivariable models, neither genotype nor constellation was associated with CMV‐DNAemia or development of CMV disease. In conclusion, the HLA‐B leader is neither associated with the occurrence nor the severity of BKPyV and CMV infections within the first year posttransplant in kidney allograft recipients. This argues against using HLA‐B leader information to guide BKPyV or CMV screening strategies.

Related

  1. Association of eplet mismatch load and allograft injury in kidney transplant recipients
    Clinical kidney journalPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Case Report: Late-onset BK polyomavirus-associated nephropathy with encephalitis, antibody-mediated rejection, and atypical hemolytic uremic syndrome: a rare overlap causing allograft dysfunction, therapeutic challenges, and multidisciplinary management
    Jie Zhou, Lichuan Yang, Jiaojiao Zhou
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. To TTV or Not to TTV? A Combined Urinary Biomarker Approach in Kidney Transplant Recipients Using Torque Teno Virus, Cell-Free DNA, and BK Polyomavirus Measurements
    Y. Alhadid, M. Mamroth, Z. Wang +4
    medRxivPreprintAll rights reservedFull textSurgery & anaesthesiamedRxiv
  4. Virologic and Exploratory Immunologic Characterization of Relapsing Human Cytomegalovirus (HCMV) DNAemia in Solid Organ Transplant Recipients: A Prospective Observational Cohort Study
    Open forum infectious diseasesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Response to antiviral therapy in haematopoietic stem cell transplant recipients with cytomegalovirus (CMV) reactivation according to the donor CMV serological status
    S. Servais, N. Dumontier, L. Biard +12
    Clinical Microbiology and InfectionPeer-reviewedLicence not statedFull text25 citedEpidemiology & public healthHAL
BibTeX
@article{ballmer2026association,
  title = {{Association of HLA‐B Leader With BK Polyomavirus and Cytomegalovirus Infections in Kidney Allograft Recipients}},
  author = {Leonie Ballmer and Matthias Diebold and Hans H. Hirsch and Gideon Hönger and Caroline Wehmeier and Stefan Schaub},
  journal = {Hla},
  year = {2026},
  month = nov,
  doi = {10.1111/tan.71082},
  url = {https://doi.org/10.1111/tan.71082},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Association of HLA‐B Leader With BK Polyomavirus and Cytomegalovirus Infections in Kidney Allograft Recipients
AU  - Leonie Ballmer
AU  - Matthias Diebold
AU  - Hans H. Hirsch
AU  - Gideon Hönger
AU  - Caroline Wehmeier
AU  - Stefan Schaub
PY  - 2026
DA  - 2026/11/06
JO  - Hla
DO  - 10.1111/tan.71082
UR  - https://doi.org/10.1111/tan.71082
AB  - Natural killer (NK) cell education and function depend on HLA‐E expression, influenced by the dimorphic HLA‐B leader peptide (−21M vs. −21T). NK cells help control BK polyomavirus (BKPyV) and cytomegalovirus (CMV) after kidney transplantation, but the HLA‐B leader's role is unclear. We retrospectively studied 700 kidney transplants with high‐resolution recipient/donor HLA typing, determining the recipient's HLA‐B leader genotype (MM 6%, MT 39%, TT 55%) and recipient/donor constellation (345/700 [49%] matched, 355/700 [51%] mismatched). Associations with 1‐year occurrence and severity of BKPyV (decoy cell shedding, BKPyV‐DNAemia, presumptive BKPyV‐associated nephropathy [BKPyVAN]) and CMV (DNAemia, disease) were assessed with univariate analyses and multivariable Cox and logistic regression. One‐year incidence of decoy cell shedding was similar across genotypes (MM 28.3%, MT 29.0%, TT 33.5%; p = 0.37) and between matched and mismatched recipients (31.0% vs. 31.8%; p = 0.79); BKPyV‐DNAemia incidence likewise did not differ by genotype (MM 19.6%, MT 16.5%, TT 18.9%; p = 0.73) or constellation (15.9% vs. 20.0%; p = 0.16). In multivariable models, neither genotype nor constellation was associated with decoy cell shedding, BKPyV‐DNAemia, or development of presumptive BKPyVAN. CMV‐DNAemia incidence also did not differ by genotype (MM 19.6%, MT 30.9%, TT 28.8%; p = 0.35) or constellation (27.0% vs. 31.0%; p = 0.25). In multivariable models, neither genotype nor constellation was associated with CMV‐DNAemia or development of CMV disease. In conclusion, the HLA‐B leader is neither associated with the occurrence nor the severity of BKPyV and CMV infections within the first year posttransplant in kidney allograft recipients. This argues against using HLA‐B leader information to guide BKPyV or CMV screening strategies.
SN  - 2059-2302
SN  - 2059-2310
ER  -